Nebido Will Emerge As Hypogonadism Treatment Leader, Indevus Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus expects Nebido to acquire the majority of the injectable testosterone hypogonadism treatment market when it launches in the U.S., the company said in an Aug. 9 earnings call
You may also be interested in...
Esprit Pharma Plans November Launch Of Proquin XR Following Licensing Deal
Esprit’s 100 sales reps will initially target marketing efforts to 8,000 urologist offices, with eventual movement to ob/gyn and family practitioners.
Indevus To Market Nebido In The U.S. Upon Approval
Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.